Sanofi (SNY) Change in Accured Expenses (2018 - 2025)
Sanofi's (SNY) quarterly Change in Accured Expenses came in at -$116.4 million in Q4 2025, down 175.01% quarter-over-quarter from -$42.3 million in Q4 2021.
Powered by 
Analysis
Sanofi (SNY) Change in Accured Expenses (2018 - 2025) Analysis & Trends
Sanofi has disclosed Change in Accured Expenses across 4 years of filings, most recently posting -$116.4 million for Q4 2025.
- In Q4 2025, Change in Accured Expenses changed N/A year-over-year to -$116.4 million; the TTM figure through Dec 2025 stood at -$619.8 million (changed N/A YoY), while the FY2025 annual figure was -$116.4 million, down 113.24% from the prior year.
- Change in Accured Expenses came in at -$116.4 million for Q4 2025 at Sanofi, down from -$42.3 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of -$42.3 million in Q4 2021 to a low of -$116.4 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | 2.32 Bn |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | 1.20 Bn |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | - |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | - |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | 360.00 Mn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | - |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | 55.78 Mn |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | 212.44 Mn |
| 10 | Incyte | 25.18 Bn | 20.65 Bn | 1.57 Bn | -204.33 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -116.40 Mn |
| Dec 31, 2021 | -42.33 Mn |
| Dec 31, 2020 | -158.57 Mn |
| Dec 31, 2018 | -302.47 Mn |